Skip to main content

Chemotherapy in Gynaecological Cancers and Newer Developments

  • 169 Accesses

Abstract

Systemic anti-cancer therapy (SACT) plays an integral role in the treatment of early and advanced gynaecological cancers. Therapeutics need to balance efficacy with toxicity and require intensive development from pre-clinical research to reach clinical practice. Conventional cytotoxic chemotherapy forms the mainstay of treatment for most gynaecological cancers but there is an increasing role for personalised medicine. Cancer management targeted to specific targets in cancer pathogenesis are becoming increasingly used and PARP inhibitors have led the way in ovarian cancer. Immunotherapy has dramatically altered cancer treatments in the past decade and has an increasing role in gynaecological cancers.

Keywords

  • Chemotherapy
  • Systemic anti-cancer therapy
  • Gynaecological cancer
  • Immunotherapy

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-94110-9_11
  • Chapter length: 16 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   149.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-94110-9
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   199.99
Price excludes VAT (USA)
Fig. 11.1
Fig. 11.2
Fig. 11.3
Fig. 11.4
Fig. 11.5
Fig. 11.6

References

  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.

    CAS  CrossRef  PubMed  Google Scholar 

  2. du Bois D, du Bois EF. Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known. Arch Int Med. 1916;17((6_2):863–71. https://doi.org/10.1001/archinte.1916.00080130010002.

    CrossRef  Google Scholar 

  3. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748–56. https://doi.org/10.1200/JCO.1989.7.11.1748.

    CAS  CrossRef  PubMed  Google Scholar 

  4. https://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm

  5. https://www.medicines.org.uk/emc/about-the-emc

  6. Rustin GJS, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419–23.

    CrossRef  Google Scholar 

  7. Lyubimova NV, Beyshembaev AM, Kushlinskiy DN, Zordania KI, Adamyan LV. Granulosa cell tumors of the ovary and inhibin B. Bull Exp Biol Med. 2011;150(5):635–8. https://doi.org/10.1007/s10517-011-1209-z.

    CAS  CrossRef  PubMed  Google Scholar 

  8. Roncati L, Lusenti B. Liquid biopsy to monitor early relapse of gynaecological malignancies. Eur J Gynaecol Oncol. 2020;41(6):849–51. https://doi.org/10.31083/j.ejgo.2020.06.5430.

    CrossRef  Google Scholar 

  9. Narayanan P, Sahdev A. The role of 18F-FDG PET CT in common gynaecological malignancies. Br J Radiol. 2017;90(1079):20170283. https://doi.org/10.1259/bjr.20170283.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  10. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1—Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7. https://doi.org/10.1016/j.ejca.2016.03.081.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  11. Drilon A, Laetsch TW, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9.

    CAS  CrossRef  Google Scholar 

  12. Kerr DJ, et al. Oxford textbook of oncology. 3rd ed. Oxford: Oxford University Press; 2016.

    CrossRef  Google Scholar 

  13. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V, Williams C, Lissoni A, Bonazzi C. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003;95(2):125–32. https://doi.org/10.1093/jnci/95.2.125.

    CrossRef  PubMed  Google Scholar 

  14. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2):105–12. https://doi.org/10.1093/jnci/95.2.105.

    CrossRef  PubMed  Google Scholar 

  15. Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2015;2015(12):CD004706. https://doi.org/10.1002/14651858.CD004706.pub5.

    CrossRef  PubMed Central  Google Scholar 

  16. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672–705. https://doi.org/10.1093/annonc/mdz062.

    CAS  CrossRef  PubMed  Google Scholar 

  17. Armstrong DK, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191–226.

    CAS  CrossRef  Google Scholar 

  18. Fotopoulou C, Hall M, Cruickshank D, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2017;213:123–39. https://doi.org/10.1016/j.ejogrb.2017.04.016.

    CrossRef  PubMed  Google Scholar 

  19. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Eng J Med. 2010;363(10):943–53. https://doi.org/10.1056/nejmoa0908806.

    CAS  CrossRef  Google Scholar 

  20. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;2016(1):CD005340. https://doi.org/10.1002/14651858.CD005340.pub4.

    CrossRef  PubMed Central  Google Scholar 

  21. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol. 2006;24:1127–35.

    CrossRef  Google Scholar 

  22. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Eng J Med. 2011;365(26):2473–83. https://doi.org/10.1056/nejmoa1104390.

    CAS  CrossRef  Google Scholar 

  23. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Eng J Med. 2011;365(26):2484–96. https://doi.org/10.1056/nejmoa1103799.

    CAS  CrossRef  Google Scholar 

  24. Rustin GJS, van der Burg MEL, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63. https://doi.org/10.1016/S0140-6736(10)61268-8.

    CrossRef  PubMed  Google Scholar 

  25. Wilson M, et al. Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease. Ann Oncol. 2017;28:727–32.

    CAS  CrossRef  Google Scholar 

  26. Gladieff L, Ferrero A, de Rauglaudre G, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol. 2012;23(5):1185–9. https://doi.org/10.1093/annonc/mdr441.

    CAS  CrossRef  PubMed  Google Scholar 

  27. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588–91. https://doi.org/10.1038/bjc.2012.307.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  28. ICON and AGO Collaborators. Paclitaxel plus platinum based chemotherapy versus conventional platinum based chemotherapy in women with relapsed ovarian cancer: the ICON/ AGO-OVAR 2.2 trial. Lancet. 2003;361:2009–106.

    Google Scholar 

  29. Pfisterer J, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707.

    CAS  CrossRef  Google Scholar 

  30. Aghajanian C, Blank SV, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.

    CAS  CrossRef  Google Scholar 

  31. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–8.

    CAS  CrossRef  Google Scholar 

  32. Van der Burg ME, de Wit R, Van Putton WL, et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pre-treated ovarian cancer. B J Cancer. 2002;7:19–25.

    CrossRef  Google Scholar 

  33. George A, et al. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. BMC Cancer. 2017;17:456. https://doi.org/10.1186/s12885-017-3440-0.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  34. Kok PS, Beale P, O’Connell RL, et al. PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. J Gynecol Oncol. 2019;30(5):e86. https://doi.org/10.3802/jgo.2019.30.e86.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  35. Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, Colombo N. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv1–iv18. https://doi.org/10.1093/annonc/mdy001.

    CAS  CrossRef  PubMed  Google Scholar 

  36. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137–54. https://doi.org/10.1158/2159-8290.CD-15-0714.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  37. Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? Nat Rev Clin Oncol. 2018;15(9):564–76. https://doi.org/10.1038/s41571-018-0055-6.

    CAS  CrossRef  PubMed  Google Scholar 

  38. https://medicines.astrazeneca.co.uk/home/oncology/hrd-tbrca-testing/hrd-testing.html

  39. https://www.foundationmedicine.com/test/foundationone-cdx

  40. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5(11):1137–54. https://doi.org/10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13. PMID: 26463832; PMCID: PMC4631624.

  41. Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–89. https://doi.org/10.1016/S1470-2045(16)30376-X.

    CAS  CrossRef  PubMed  Google Scholar 

  42. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Eng J Med. 2018;379(26):2495–505. https://doi.org/10.1056/nejmoa1810858.

    CAS  CrossRef  Google Scholar 

  43. Poveda A, Floquet A, Ledermann JA, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;22(5):620–31. https://doi.org/10.1200/jco.2020.38.15_suppl.6002.

    CrossRef  Google Scholar 

  44. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Eng J Med. 2016;37(32)):2968–73. https://doi.org/10.1056/nejmoa1611310.

    CrossRef  Google Scholar 

  45. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61. https://doi.org/10.1016/S0140-6736(17)32440-6.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  46. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Eng J Med. 2019;381(25):2416–28. https://doi.org/10.1056/nejmoa1911361.

    CAS  CrossRef  Google Scholar 

  47. Morice PM, Leary A, et al. Myelodysplastic syndromeand acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8(2):e122–34.

    CrossRef  Google Scholar 

  48. Poveda A, Floquet A, et al. SOLO2/ENGOTOV21 investigators. Olaparib tablets as maintainance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation: a final analysis of a double blind, randomised, placebo controlled phase 3 trial. Lancet Oncol. 2021;22(5):620–31. https://doi.org/10.1016/S1470-2045(21)00073-5.

    CAS  CrossRef  PubMed  Google Scholar 

  49. Grabowski JP, Harter P, Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016;140(3):457–62. https://doi.org/10.1016/j.ygyno.2016.01.022.

    CrossRef  PubMed  Google Scholar 

  50. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol. 2017;35(10):1103. https://doi.org/10.1200/JCO.2016.71.0632.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  51. Monk BJ, Grisham RN, Banerjee S, et al. MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J Clin Oncol. 2020;38(32):3753. https://doi.org/10.1200/JCO.20.01164.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  52. Gershenson D. A randomised Phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low grade serous or peritoneal cancer. Gynecol Oncol. 2020;159(Suppl 1):v897–8. https://doi.org/10.1016/j.ygyno.2020.06.045.

    CrossRef  Google Scholar 

  53. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12–39. https://doi.org/10.1136/ijgc-2020-002230.

    CrossRef  PubMed  Google Scholar 

  54. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273–85. https://doi.org/10.1016/S1470-2045(19)30395-X.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  55. Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. 2012;2012(8):CD003915. https://doi.org/10.1002/14651858.CD003915.pub4.

    CrossRef  PubMed Central  Google Scholar 

  56. Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M, Zaino R. Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;125(3):771. https://doi.org/10.1016/j.ygyno.2012.03.034.

    CrossRef  Google Scholar 

  57. Sundar S, Balega J, Crosbie E, et al. BGCS uterine cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2017;213:71–97. https://doi.org/10.1016/j.ejogrb.2017.04.015.

    CrossRef  PubMed  Google Scholar 

  58. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68. https://doi.org/10.1038/s41577-020-0306-5.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  59. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. https://doi.org/10.1016/j.immuni.2013.07.012.

    CAS  CrossRef  PubMed  Google Scholar 

  60. Yoshino T, et al. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendationfor tumour agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol. 2020;31(7):861–72. https://doi.org/10.1016/j.annonc.2020.03.299.

    CAS  CrossRef  PubMed  Google Scholar 

  61. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–42. https://doi.org/10.1093/annonc/mdx225.

    CAS  CrossRef  PubMed  Google Scholar 

  62. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv72–83. https://doi.org/10.1093/annonc/mdx220.

    CAS  CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer Pascoe .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Tilby, M., Williams, S., Pascoe, J. (2022). Chemotherapy in Gynaecological Cancers and Newer Developments. In: Singh, K., Gupta, B. (eds) Gynecological Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-94110-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-94110-9_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-94109-3

  • Online ISBN: 978-3-030-94110-9

  • eBook Packages: MedicineMedicine (R0)